Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Loncastuximab tesirine by Swedish Orphan Biovitrum for Post-Transplant Lymphoproliferative Disorder: Likelihood of Approval
Loncastuximab tesirine is under clinical development by Swedish Orphan Biovitrum and currently in Phase II for Post-Transplant Lymphoproliferative Disorder. According...
Loncastuximab tesirine by Swedish Orphan Biovitrum for Splenic Marginal Zone B-Cell Lymphoma: Likelihood of Approval
Loncastuximab tesirine is under clinical development by Swedish Orphan Biovitrum and currently in Phase II for Splenic Marginal Zone B-Cell...
Loncastuximab tesirine by Swedish Orphan Biovitrum for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma): Likelihood of Approval
Loncastuximab tesirine is under clinical development by Swedish Orphan Biovitrum and currently in Phase II for Extranodal Marginal Zone B-Cell...
Loncastuximab tesirine by Swedish Orphan Biovitrum for Marginal Zone B-cell Lymphoma: Likelihood of Approval
Loncastuximab tesirine is under clinical development by Swedish Orphan Biovitrum and currently in Phase I for Marginal Zone B-cell Lymphoma....
Loncastuximab tesirine by Swedish Orphan Biovitrum for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Loncastuximab tesirine is under clinical development by Swedish Orphan Biovitrum and currently in Phase I for Chronic Lymphocytic Leukemia (CLL)....
Loncastuximab tesirine by Swedish Orphan Biovitrum for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma): Likelihood of Approval
Loncastuximab tesirine is under clinical development by Swedish Orphan Biovitrum and currently in Phase II for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma)....
Loncastuximab tesirine by Swedish Orphan Biovitrum for Burkitt Lymphoma: Likelihood of Approval
Loncastuximab tesirine is under clinical development by Swedish Orphan Biovitrum and currently in Phase I for Burkitt Lymphoma. According to...
Loncastuximab tesirine by Swedish Orphan Biovitrum for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval
Loncastuximab tesirine is under clinical development by Swedish Orphan Biovitrum and currently in Phase I for B-Cell Non-Hodgkin Lymphoma. According...